← Leaderboards
Paul Colussi
Tetragenetics, Inc.
$1,867,165
Attributed
$1,867,165
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $821K · FY2010–17$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,867,165 · 2
By mechanism
R44$1,689,529 · 1
R43$177,636 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Therapeutic Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$217,310,389
- Lawrence Corey · Fred Hutchinson Cancer Center$212,381,140
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$157,078,989
- Judith S. Currier · University Of California Los Angeles$142,797,193
- David Heimbrook · Leidos Biomedical Research, Inc.$127,285,582
Research focus
Therapeutic AntibodiesRecombinant ProteinsProteinsTetrahymena ThermophilaYeastsCellsLaboratoriesProductionRecombinantsTetrahymenaTissue/Cell CultureBaseCommunicable DiseasesTechnologyCostGrowthMalignant NeoplasmsPharmaceutical PreparationsAntibody FormationBiologicalBasic ScienceAttentionApplied ResearchCommunities
Grant awards (4)
Expanding the use of Tetrahymena as a protein expression platform$109,620
R44 · FY2017 · GM · contact PI
Expanding the use of Tetrahymena as a protein expression platform$758,950
R44 · FY2016 · GM · contact PI
Expanding the use of Tetrahymena as a protein expression platform$820,959
R44 · FY2015 · GM · contact PI
Novel methods for high-level expression of aglycosylated or fully glycosylated mo$177,636
R43 · FY2010 · GM · contact PI